“GLP-1s (like Ozempic) cure alcoholism and addiction.”
What the evidence shows
Many people report reduced desire for alcohol on a GLP-1, and there is now genuine trial evidence: a 2026 Lancet randomized trial of semaglutide in people with alcohol use disorder found fewer heavy-drinking days and less craving than placebo, and larger trials are in progress. The reward-system effects are a plausible mechanism.
What we still don’t know
The strongest trial so far was single-center, modest in size, and short; the definitive phase-3 results aren't in. How large and durable the effect is, who benefits, and whether it holds for other addictions are all open. No GLP-1 is FDA-approved to treat alcohol use disorder or any addiction.
Why the claim misleads
"Cure" wildly overshoots the evidence. There is a real, exciting early signal — but a promising randomized trial is not a cure, and using an approved obesity/diabetes drug for addiction is off-label and unproven. Honest framing: a lead worth watching, not a solved problem.
Source: Semaglutide vs placebo in alcohol use disorder — randomized controlled trial. The Lancet. 2026.
Graded by The Peptide Era · evidence, not hype